Kyndryl Holdings Inc vs Twist Bioscience Corp — how do they compare? Kyndryl Holdings Inc trades at $12.15 (market cap $2.69B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Twist Bioscience Corp is far larger — about 2× Kyndryl Holdings Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals.
| KD | TWST | |
|---|---|---|
Market Cap | $2.69B | $5.45B |
Sector | Technology | Health |
52-Week High | $39.47 | $102.88 |
52-Week Low | $10.59 | $24.16 |
Enterprise Value | $5.03B | $5.37B |
Signals from Pluang's Aura AI — not financial advice
KD trades at $12.19, up 0.33% on the day, with a neutral technical signal. The company reported revenue of $15.06B in 2025, with net income turning positive to $252M after three years of losses. Recent news includes a partnership with Microsoft for sovereignty solutions and ongoing legal investigations into officers and directors.
The outlook is mixed; improving profitability and a low P/E of 14.38 suggest value, but recent earnings misses and legal scrutiny pose risks. Analyst consensus is a $14.00 price target with a hold rating, indicating cautious optimism amid transformation efforts.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →